Contribution of cytochrome P450 isoforms to gliquidone metabolism in rats and human

Xenobiotica

Volumn 44, Issue 3, 2014, Pages 229-234

  He, Fang ^a,b   Li, Yun ^a,c   Zeng, Caiwen ^a,b   Xia, Chunhua ^a   Xiong, Yuqing ^a   Zhang, Hong ^a   Huang, Shibo ^a   Liu, Mingyi ^a  

^a NANCHANG UNIVERSITY   (China)

^b Jiangxi Province Cancer Hospital   (China)

^c Jiangxi Nursing Occupation Technology College   (China)

Author keywords

CYP450 isoforms; Gliquidone; Metabolism contribution; Metabolism pathway

Indexed keywords

CYTOCHROME P450 1A; CYTOCHROME P450 1A2; CYTOCHROME P450 2C; CYTOCHROME P450 2C11; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D; CYTOCHROME P450 2D1; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A1; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; GLIQUIDONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; HUMAN; IN VITRO STUDY; LIVER CLEARANCE; LIVER MICROSOME; NONHUMAN; PREDICTION; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; FLUORESCENCE; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; RATS; SPECIES SPECIFICITY; SULFONYLUREA COMPOUNDS;

EID: 84893572156     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.831957     Document Type: Article

References (19)

1. Arbus C, Benyamina A, Llorca PM, et al. (2007). Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci 32:357-66.
2. Chen R, Zhou Y, Tian J, et al. (2009). Determination of gliqudone in human plasma by HPLC-fluorescence and bioequivalence of 2 gliqudone tablets. Centr South Pharm 4:282-5.
3. Eagling VA, Tjia JF, Back DJ. (1998). Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol 45:107-14.
4. Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H. (2010). Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab 11:678-85.
5. Faucette SR, Hawke RL, Shord SS, et al. (2001). Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation. Drug Metab Dispos 29:1123-9.
6. Grzeszczak W, Strojek K. (1993). Effect of short term hypoglycemic treatment with gliclazide and gliquidone on platelet function in patients with diabetes mellitus type II. Pol Tyg Lek 48:38-9.
7. Holstein A, Hahn M, Patzer O, et al. (2011). Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol 67:471-6.
8. Holstein A, Hammer C, Hahn M, et al. (2010). Severe sulfonylureainduced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients. Expert Opin Drug Saf 9:675-81.
9. Holstein A, Plaschke A, Ptak M, et al. (2005). Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmcol 60:103-6.
10. Malaisse WJ. (2006). Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data. Drug R D 7:331-7.
11. Ma XC, Ning J, Ge GB, et al. (2011). Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey, and human. Drug Metab Dispos 39:675-82.
12. Narimatsu S, Yonemoto R, Saito K, et al. (2006). Oxidative metabolism of 5-methoxy-N, N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes. Biochem Pharmacol 71:1377-85.
13. Ramirez J, Innocenti F, Schuetz EG, et al. (2004). CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. Drug Metab Dispos 32: 930-6.
14. Tang C, Shou M, Mei Q, et al. (2000). Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 293:453-9.
15. Tuerk TR, Bandur S, Nuernberger J, et al. (2008). Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation. Clin Nephrol 70:26-30.
16. Wang X, Yeung JH. (2010). Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats. J Pharm Pharmacol 62: 1077-83.
17. Yamazaki H. (2000). Roles of human cytochrome P450 enzymes involved in drug metabolism and toxicological studies. Yakugaku Zasshi 120:1347-57.
18. Yanardag R, Ozsoy-Sacan O, Orak H, Ozgey Y. (2005). Protective effects of glurenorm (gliquidone) treatment on the liver injury of experimental diabetes. Drug Chem Toxicol 28:483-47.
19. Youdim K, Dodia R. (2010). Comparison between recombinant P450s and human liver microsomes in the determination of cytochrome P450 Michaelis-Menten constants. Xenobiotica 40:235-44.